SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
| EULEXIN TAB 250MG | 250 mg | Tablet · Oral use | 100 Blister | SAR 472.50 | NCE · Prescription | SCHERING-PLOUGH | Withdrawn by MAH · Not Marketed |
| EULEXIN TAB 250MG | 250 mg | Tablet · Oral use | 20 Blister | SAR 109.65 | NCE · Prescription | SCHERING-PLOUGH | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
| FLUTAMIDE | 125MG | capsule · oral | WAYLIS THERAP | Prescription | 18 Sep 2001 |
| EULEXIN | 125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | SCHERING | Discontinued | 27 Jan 1989 |
| FLUTAMIDE | 125MG | capsule · oral | CHARTWELL RX | Discontinued | 18 Sep 2001 |
| FLUTAMIDE | 125MG | capsule · oral | ACTAVIS LABS FL INC | Discontinued | 18 Sep 2001 |
| FLUTAMIDE | 125MG | capsule · oral | CIPLA | Discontinued | 19 Sep 2001 |
| FLUTAMIDE | 125MG | capsule · oral | PHARMOBEDIENT | Discontinued | 9 May 2003 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
| FLUTAMIDE | 02238560 | 250 MG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
| NHS Drug Tariff | Flutamide 250mg tablets | £167.88 | 84 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 8.2.4. Hormones and antihormones · complementary
Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.